Antiretroviral therapy: dolutegravir sets SAIL(ING)

被引：4
|
作者：
Boyd, Mark A. [1 ]
Donovan, Basil [1 ]
机构：
[1] Univ New S Wales, Kirby Inst Infect & Immun Soc, Sydney, NSW 2052, Australia
来源：
LANCET | 2013年 / 382卷 / 9893期
关键词：
CO-FORMULATED ELVITEGRAVIR; HIV-1; INFECTION; DOUBLE-BLIND; INITIAL TREATMENT; CONTROLLED-TRIAL; RALTEGRAVIR; EMTRICITABINE; COBICISTAT; TENOFOVIR; EFAVIRENZ;
D O I：
10.1016/S0140-6736(13)61456-7
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：664 / 666
页数：3
相关论文
共 50 条
  • [1] Advances in antiretroviral therapy
    Arribas, Jose R.
    Eron, Joseph
    CURRENT OPINION IN HIV AND AIDS, 2013, 8 (04) : 341 - 349
  • [2] Quad's in it for antiretroviral therapy?
    Schrijvers, Rik
    Debyser, Zeger
    LANCET, 2012, 379 (9835) : 2403 - 2405
  • [3] UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma
    Simiele, Marco
    Ariaudo, Alessandra
    De Nicolo, Amedeo
    Favata, Fabio
    Ferrante, Martina
    Carcieri, Chiara
    Bonora, Stefano
    Di Perri, Giovanni
    De Avolio, Antonio
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2017, 138 : 223 - 230
  • [4] Severe Thrombocytopenia During Dolutegravir-containing Antiretroviral Therapy
    Nakaharai, Kazuhiko
    Miyajima, Makiko
    Kobayashi, Hiroaki
    Shimizu, Akihiro
    Hosaka, Yumiko
    Horino, Tetsuya
    Hori, Seiji
    INTERNAL MEDICINE, 2017, 56 (16) : 2229 - 2232
  • [5] Initial antiretroviral therapy: The dilemmas ahead
    Arribas, Jose R.
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2013, 31 (02): : 68 - 70
  • [6] Use of Dolutegravir for Antiretroviral Therapy for Women of Childbearing Age
    Atkin, Kathryn
    Scannell, Meredith
    Nicholas, Patrice K.
    JOGNN-JOURNAL OF OBSTETRIC GYNECOLOGIC AND NEONATAL NURSING, 2019, 48 (06): : 664 - 673
  • [7] Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
    Mesplede, Thibault
    Wainberg, Mark A.
    VIRUSES-BASEL, 2014, 6 (09): : 3377 - 3385
  • [8] Dolutegravir as first-line antiretroviral therapy in South Africa: Beware the one-size-fits-all approach
    Bangalee, A.
    Hanley, S.
    Bangalee, V
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2022, 112 (10): : 787 - 790
  • [9] Candidates for inclusion in a universal antiretroviral regimen: dolutegravir
    Cahn, Pedro
    CURRENT OPINION IN HIV AND AIDS, 2017, 12 (04) : 318 - 323
  • [10] Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy
    Hailu, Workagegnehu
    Tesfaye, Tsebaot
    Tadesse, Abilo
    INTERNATIONAL MEDICAL CASE REPORTS JOURNAL, 2021, 14 : 503 - 507
12345